Description: Corestem, Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. Corestem, Inc. was founded in 2003 and is based in Seongnam, South Korea.
Home Page: www.corestem.com
24, Pangyo-ro 255beon-gil
Seongnam-si,
South Korea
Phone:
82 2 497 3711
Officers
| Name | Title |
|---|---|
| Ms. Kyung-Suk Kim | Chief Exec. Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 10.0389 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 67 |